Vanessa Tassell

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Medicine, Oncology, Pharmacology +15

Institutional implementation of clinical tumor profiling on an unselected cancer population

Lynette M. Sholl, T. Khanh, Priyanka Shivdasani et al. · JCI Insight · 2016 · 448 citations · Full text

Medicine, Pathology, Cancer Genetics +16

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

Suzanne George, Jean‐Yves Blay, Paolo G. Casali et al. · European Journal of Cancer · 2009 · 368 citations

Medicine, Oncology, Pharmacology +13

Initial phase II results with crizotinib in advanced <i>ALK</i>-positive non-small cell lung cancer (NSCLC): PROFILE 1005.

Lucio Crinò, D. Kim, Gregory J. Riely et al. · Journal of Clinical Oncology · 2011 · 174 citations

Medicine, Oncology, Pharmacology +15

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

John Crown, Véronique Dièras, Elżbieta Starosławska et al. · Journal of Clinical Oncology · 2013 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17